EML4-ALK Inhibitors (IC50, Ki)
Structure ▲ ▼ | Compound Name ▲ ▼ | Standard Type ▲ ▼ | Standard Values (in nM) ▲ ▼ |
Crizotinib | IC50 | 605.0 [1] | |
Lorlatinib | IC50 | 9.0 [1] | |
(16R)-19-Amino-13-fluoro-3,5,8,16-tetramethyl-17-oxa-4,8,20-triaza-5-azoniatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10(15),11,13,18,20-octaen-9-one | IC50 | 0.7 [1], 14.0 [2] | |
Alectinib | IC50 | 2.0 [1] | |
Ceritinib | IC50 | 41.0 [1] | |
Alk-IN-1 | IC50 | 5.0 [1] | |
Entrectinib | IC50 | 28.0 [1] | |
JH-VIII-157-02 | IC50 | 2.0 [1] | |
9-Ethyl-6,6-dimethyl-8-[1-(oxan-4-yl)pyrazol-4-yl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile | IC50 | 78.0 [1] | |
9-Ethyl-6,6-dimethyl-11-oxo-8-(1-piperidin-4-ylpyrazol-4-yl)-5H-benzo[b]carbazole-3-carbonitrile | IC50 | 40.0 [1] |
References
This online tool may be cited as follows
MLA | "Quest Database™ EML4-ALK Inhibitors (IC50, Ki)." AAT Bioquest, Inc., 21 Nov. 2024, https://www.aatbio.com/data-sets/eml4-alk-inhibitors-ic50-ki. | |
APA | AAT Bioquest, Inc. (2024, November 21). Quest Database™ EML4-ALK Inhibitors (IC50, Ki). AAT Bioquest. https://www.aatbio.com/data-sets/eml4-alk-inhibitors-ic50-ki. | |
BibTeX | EndNote | RefMan |